SGLT2 Inhibitors - Cardiovascular Benefits - Regner Health Solutions


One of the primary cardiovascular benefits of SGLT2 inhibitors is the reduction in major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. This means that these inhibitors not only help in managing blood sugar levels but also significantly decrease the risk of heart attack, stroke, and other cardiovascular events. Moreover, secondary benefits are observed when using SGLT2 inhibitors. These include reducing HbA1c levels, an essential measure of long-term blood sugar control. Additionally, these inhibitors have been associated with weight loss, making them particularly beneficial for individuals who struggle with obesity or are aiming for weight management. Another secondary benefit of SGLT2 inhibitors is reduced systolic blood pressure (SBP). Lowering high blood pressure positively impacts cardiovascular health and can decrease heart disease risk in diabetic patients. Notably, SGLT2 inhibitors have demonstrated an excellent safety profile regarding cardiovascular outcomes while providing these secondary benefits. This is crucial to their usage, ensuring patients reap the benefits without experiencing adverse cardiovascular effects. Learn more about SGLT2 inhibitors and other services we offer: regnerhealthsolutions.com/sglt2-inhibitors/

from Flickr https://flic.kr/p/2pKM3WU
via https://regnerhealthsolutions.com/

Comments

Popular posts from this blog

Semaglutide Clinic Spring Park, MN

Medical Weight Loss Metabolic Rate - Basal Metabolic Rate (Bmr) - Regner Health Solutions